GoodRx Holdings (GDRX) Cash & Equivalents (2019 - 2026)

GoodRx Holdings has disclosed Cash & Equivalents across 8 years of filings, most recently posting $296.1 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 5.26% year-over-year to $296.1 million; the TTM figure through Jun 2026 stood at $296.1 million (up 5.26% YoY), while the FY2025 annual figure was $261.8 million, down 41.6% from the prior year.
• Cash & Equivalents came in at $296.1 million for Q2 2026 at GoodRx Holdings, up from $235.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $845.4 million in Q1 2022 to a low of $235.7 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $535.1 million, with a median of $529.1 million recorded in 2024.
• Year-over-year, Cash & Equivalents grew 9.07% in 2023 and slumped 46.69% in 2024.
• Over 5 years, Cash & Equivalents stood at $757.2 million in 2022, then retreated by 11.21% to $672.3 million in 2023, then slumped by 33.31% to $448.3 million in 2024, then sank by 41.6% to $261.8 million in 2025, then grew by 13.1% to $296.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $296.1 million in Q2 2026, $235.7 million in Q1 2026, and $261.8 million in Q4 2025.